Cardiometabolic Health Congress Regional Conference Series
http://www.cardiometabolichealth.org/2016/regional/chicago.html
Creators of Cycloset®*, the first and only FDA approved sympatholytic dopamine D2 receptor agonist for the treatment of type 2 diabetes.
*See full prescribing info
http://www.cardiometabolichealth.org/2016/regional/chicago.html
https://www.streetinsider.com/Press+Releases/VeroScience+is+Pleased+to+Support+Independent+Research+from+the+Laboratory+of+Dr.+DeFronzo+and+Team+at+UT+Health+Science+Center,+San+Antonio/11731961.html
https://www.prnewswire.com/news-releases/veroscience-continues-to-explore-clinical-benefits-of-circadian-neuroendocrine-resetting-therapy-with-six-papers-presented-at-2016-american-diabetes-association-scientific-sessions-june-10-14-300283267.html
http://professional.diabetes.org/meeting/scientific-sessions/76th-scientific-sessions
http://professional.diabetes.org/meeting/other/30th-annual-clinical-conference-diabetes
http://www.cardiometabolichealth.org/2016/regional/atlanta.html
http://www.clevelandclinicmeded.com/live/courses/diabetesday/default.asp
https://medcitynews.com/2015/08/can-deconstructing-the-biological-clock-help-treat-diabetes-and-cancer/comment-page-1/
http://medcitynews.com/2015/08/can-deconstructing-the-biological-clock-help-treat-diabetes-and-cancer/
http://www.prnewswire.com/news-releases/two-peer-reviewed-studies-focusing-on-unique-therapeutic-impact-of-verosciences-cycloset-recently-published-in-journal-of-diabetes-research-300098977.html
